Attention-deficit-hyperactivity disorder (ADHD) affects over 40 million people—children, adolescents, and adults—across the major pharmaceutical markets. The key treatment goals for both pediatric and adult ADHD include controlling the core symptoms of the condition—inattention and/or hyperactivity/impulsivity—as well as improving patients’ overall functioning and quality of life. Psychostimulants are the predominant drug class prescribed for both pediatric and adult ADHD, though nonstimulant therapies serve as alternative or later-line options. Shortcomings in existing therapies, however, represent potential areas of opportunity for emerging therapies to be differentiated from competitors. Furthermore, recognition and diagnosis of adult ADHD continues to grow, particularly in the United States, but this population remains underdetected and undertreated, representing a sizable market opportunity.
Questions Answered
- What is the current state of treatment for pediatric and adult ADHD across the G7, and what needs are left unfulfilled by current ADHD therapies?
- How has the entrance of generic competition to key drugs (e.g., Eli Lilly’s Strattera [atomoxetine]) modified the ADHD treatment landscape?
- How have newer-to-market and brand-only agents (e.g., Shire’s Mydayis, Neos Therapeutics’ Adzenys ER) been incorporated into medical practice? What are physicians’ perception of these therapies?
- What emerging therapies do ADHD thought leaders consider the most promising for pediatric ADHD and adult ADHD?
Product description: Disease Landscape & Forecast provides comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Approximately 16 country-specific interviews with thought-leading psychiatrists and pediatricians, supported by survey data.
Epidemiology: Prevalence of ADHD by country, segmented by pediatric and adult ADHD.
Emerging therapies: Phase II: 6 drugs; Phase III: 6 drugs; preregistration/registration: 2 drugs. Coverage of select preclinical and Phase I products.
Market forecast features: Ten-year, annualized, drug-level sales and patient share of key ADHD therapies through 2027, segmented by brands/generics and pediatric/adult ADHD.
Key companies: Shire, Janssen, Novartis, Eli Lilly, Arbor Pharmaceuticals, Neos Pharmaceuticals, Pfizer, Ironshore Pharmaceuticals, Supernus Pharmaceuticals, Sunovion.
Key drugs: Vyvanse, Concerta, Strattera, Adderall, Ritalin, Mydayis, Focalin, Dexedrine, Intuniv.
Joyce Spadafora, A.L.M.
Joyce Spadafora, A.L.M., is a senior analyst on the CNS/Ophthalmology Disorders team. She authors content on various chronic pain, psychiatric, and neurological indications. Prior to joining the company, she spent several years in the biotech industry focusing on new product development and consulting. She holds a master’s degree in extension studies in psychology from Harvard University and a bachelor’s of science in mechanical engineering with biology from the Massachusetts Institute of Technology.
Andrea Witt, Ph.D.
Andrea S. Witt, Ph.D., is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.
Niyati Khetarpal, Ph.D.
Niyati Khetarpal, M.Sc., M.B.A., Ph.D., is a senior analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Dr. Khetarpal obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology in New Delhi, where she conducted research on Dengue virus vaccines. In 2014, she received a Fulbright-Nehru doctoral scholarship for her research on Dengue and West Nile virus envelope proteins.
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
Shefali Gulati, M.B.A.
Shefali Gulati, M.B.A., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She has authored several CNS/Ophthalmology reports, including U.S. Treatment Algorithms, Unmet need, Special topics. Previously, Ms. Gulati was a knowledge management associate with ZS Associates, where she worked on multiple client projects pertaining to real-world claims data analysis, opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds an M.B.A. in pharmaceutical management from the National Institute of Pharmaceutical Education and Research and a bachelor’s degree in pharmacy from the Delhi Institute of Pharmaceutical Sciences and Research.